The event is an earnings conference call for a group of analysts and investors to discuss the company's unaudited standalone financial results for the quarter and half year ended September 30, 2026 (Q2 & H1 FY27).
The call is scheduled for Thursday, November 5, 2026, at 5:00 PM Indian Standard Time (IST).
The stated purpose is to discuss the financial results for the specified period.
The meeting is scheduled after the earnings announcement, as it is intended to discuss already announced results.
Management participants include: Mr. Shiven Arora (Managing Director), Mr. V.K. Singh (Chief Operating Officer), Mr. Ganesh Karuppannan (Chief Financial Officer), and Mr. Sanjay Sinha (Deputy Chief Financial Officer).
The disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and implies standard compliance, meaning no unpublished price sensitive information (UPSI) will be shared.
No specific mention is made of a presentation, earnings deck, transcript, or recording being made available post-call.
Additional Notes Section
The document includes logistical details for the call, such as universal access numbers and international toll-free numbers for the USA, UK, Singapore, and Hong Kong.
A DiamondPass™ link is provided for direct access without wait time.
Participants are requested to dial in 10 minutes before the scheduled time.
The document contains no financial data, figures, or performance highlights; it is purely an intimation and invite for the earnings call.
The company is described as a global, science-led pharmaceutical company operating as a CDMO (Contract Development and Manufacturing Organization) with capabilities in contrast media intermediates and high-intensity sweeteners.
Key clients mentioned include GE Healthcare, Guerbet, Bracco, Colgate Palmolive (India) Limited, and Unilever.
Contact information is provided for the Company Secretary (Ms. Sweta Poddar) and the EY Investor Relations team (Diwakar Pingle and Kunal Bhoite).
